Blocking IL-1 in systemic inflammation

J Exp Med. 2005 May 2;201(9):1355-9. doi: 10.1084/jem.20050640.

Abstract

A growing number of systemic inflammatory diseases characterized in part by recurrent fevers, leukocytosis, anemia, and elevated acute phase proteins are linked to interleukin (IL)-1 activity since rapid and sustained resolution is observed upon specific blockade of IL-1 receptors. Rapid resolution of systemic and local inflammation is now also reported in systemic onset juvenile idiopathic arthritis (SoJIA). Loss of control of the secretion of IL-1beta might be a common mechanism explaining the aberrant activity of IL-1 in these diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Arthritis, Juvenile / drug therapy
  • Arthritis, Juvenile / etiology
  • Arthritis, Juvenile / metabolism*
  • Humans
  • Inflammation / etiology
  • Inflammation / metabolism*
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / metabolism*
  • Models, Biological*
  • Receptors, Interleukin-1 / antagonists & inhibitors*
  • Sialoglycoproteins / metabolism
  • Sialoglycoproteins / therapeutic use
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Receptors, Interleukin-1
  • Sialoglycoproteins
  • Tumor Necrosis Factor-alpha